Health Condition 1: E103- Type 1 diabetes mellitus with ophthalmic complications Health Condition 2: E113- Type 2 diabetes mellitus with ophthalmic complications
Conditions
Interventions
Intervention1: PATIENTS REQUIRING TREATMENT WOULD BE GIVEN AS AND WHEN REQUIRED ACCORDING TO THE STANDARD OPERATIVE PROTOCOL: ANTI-VGEF DRUGS WOULD BE GIVEN
-INJ BEVACIZUMAB 1.25 mg/0.05ml
-INJ RANIBI
Sponsors
Sankara Eye Hospital Bangalore
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients within Age group of 30 years to 60 years 2.Patients with Non-Proliferative Diabetic Retinopathy (NPDR)(Both Type1 and Type2 Diabetes Mellitus) 3. Patients with Diabetes with no evidence of Diabetic Retinopathy 4.Patients with NPDR with Centre involving Macular Edema undergoing treatment
Exclusion criteria
Exclusion criteria: 1. Patients with Proliferative Diabetic Retinopathy(PDR) 2. Patients with Non-centre involving Macular Edema 3. Lens or other media opacity which precludes imaging 4. Clinical evidence of other ocular or retinal pathology 5. Patients undergone previous treatment(Intravitreal injection or laser) 6. Patients with diabetic Tractional retinal detachement or Complete retinal detachment (TRD/CRD)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess changes in the Macular Capillary Vessel Density in patients with Diabetic Retinopathy and following treatmentTimepoint: baseline and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess if there is any association between vessel density and HbA1c levels 2. To evaluate association of vessel density with visual acuity 3. To assess changes in the Central Retinal ThicknessTimepoint: baseline and 6 months | — |
Countries
India
Contacts
Public ContactDr Kirtika Jain
Sankara Eye Hospital, Bangalore
Outcome results
None listed